BIOMAT Database Logo BIOMAT Database Logo

A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis. 1990

G Saracco, and F Rosina, and M R Torrani Cerenzia, and V Lattore, and L Chiandussi, and V Gallo, and R Petrino, and A G De Micheli, and E Donegani, and A Solinas
Division of Gastroenterology, Molinette Hospital, Turin, Italy.

Eighty patients with chronic non-A, non-B hepatitis completed a randomized controlled trial of the therapeutic efficacy of recombinant interferon alfa-2b. Twenty-nine received 1 million units and 26 received 3 million units of interferon subcutaneously thrice weekly for 6 months, and 25 were controls. Normalization or a significant decrease of alanine aminotransferase values was obtained in 19/29 (66%) patients treated with 1 million units, in 18/26 (69%) patients treated with 3 million units and in one control patient (4%, p less than 0.05). However, when control patients were randomized after the initial 24 weeks to receive 1 or 3 million units of interferon for 48 weeks, 12/14 (86%) patients receiving 3 million units responded to therapy versus 3/11 patients receiving 1 million units (27%, p less than 0.05). After a 1 to 6 months follow-up period post treatment, an alanine aminotransferase relapse was observed in 18/30 (60%) responders to 3 million units and in 17/22 (77%) responders to 1 million units. Cirrhotic patients responded less than patients with non-cirrhotic disease (47 vs. 78%, p less than 0.05). Only responders treated with 3 million units significantly ameliorated their histologic picture (pre-therapy Knodell's index = 8.9, post-therapy = 6.0, p less than 0.05). The data confirm that treatment with interferon is of benefit in patients with chronic non-A, non-B hepatitis.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D005260 Female Females
D006526 Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown. Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted,Parenterally-Transmitted Non-A, Non-B Hepatitis,PT-NANBH,Parenterally Transmitted Non A, Non B Hepatitis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077190 Interferon alpha-2 Alpha interferon encoded by the human IFNA2 gene. Recombinant forms are used in the treatment of CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; KAPOSI SARCOMA; MELANOMA; and HAIRY CELL LEUKEMIA. IFN-alpha 2,IFN-alpha-2,IFNalpha-2b, Recombinant,Interferon alfa-2a,Interferon alfa-2b,Interferon alpha-2b, Recombinant,Interferon alpha-A,Interferon-alpha 2,Intron A (Interferon),LeIF A,Reaferon,Recombinant Interferon alpha-2a,Recombinant Interferon alpha-2b,Ro 22-8181,Roferon-A,Sch-30500,Viferon,IFNalpha 2b, Recombinant,Interferon alfa 2a,Interferon alfa 2b,Interferon alpha 2,Interferon alpha 2b, Recombinant,Interferon alpha A,Interferon alpha-2a, Recombinant,Recombinant IFNalpha-2b,Recombinant Interferon alpha 2a,Recombinant Interferon alpha 2b,Ro 22 8181,Ro 228181,Roferon A,RoferonA,Sch 30500,Sch30500
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000410 Alanine Transaminase An enzyme that catalyzes the conversion of L-alanine and 2-oxoglutarate to pyruvate and L-glutamate. (From Enzyme Nomenclature, 1992) EC 2.6.1.2. Alanine Aminotransferase,Glutamic-Pyruvic Transaminase,SGPT,Alanine-2-Oxoglutarate Aminotransferase,Glutamic-Alanine Transaminase,Alanine 2 Oxoglutarate Aminotransferase,Aminotransferase, Alanine,Aminotransferase, Alanine-2-Oxoglutarate,Glutamic Alanine Transaminase,Glutamic Pyruvic Transaminase,Transaminase, Alanine,Transaminase, Glutamic-Alanine,Transaminase, Glutamic-Pyruvic

Related Publications

G Saracco, and F Rosina, and M R Torrani Cerenzia, and V Lattore, and L Chiandussi, and V Gallo, and R Petrino, and A G De Micheli, and E Donegani, and A Solinas
Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial.
May 1998, Gastroenterology,
G Saracco, and F Rosina, and M R Torrani Cerenzia, and V Lattore, and L Chiandussi, and V Gallo, and R Petrino, and A G De Micheli, and E Donegani, and A Solinas
Interferon alfa-2b for chronic hepatitis B.
February 1991, The New England journal of medicine,
G Saracco, and F Rosina, and M R Torrani Cerenzia, and V Lattore, and L Chiandussi, and V Gallo, and R Petrino, and A G De Micheli, and E Donegani, and A Solinas
A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.
August 2001, Hepatology (Baltimore, Md.),
G Saracco, and F Rosina, and M R Torrani Cerenzia, and V Lattore, and L Chiandussi, and V Gallo, and R Petrino, and A G De Micheli, and E Donegani, and A Solinas
Interferon alfa-2b therapy for chronic hepatitis.
May 1997, American family physician,
G Saracco, and F Rosina, and M R Torrani Cerenzia, and V Lattore, and L Chiandussi, and V Gallo, and R Petrino, and A G De Micheli, and E Donegani, and A Solinas
Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
December 2004, JAMA,
G Saracco, and F Rosina, and M R Torrani Cerenzia, and V Lattore, and L Chiandussi, and V Gallo, and R Petrino, and A G De Micheli, and E Donegani, and A Solinas
Randomised controlled trial of interferon alfa (lymphoblastoid interferon) in chronic non-A non-B hepatitis.
January 1989, BMJ (Clinical research ed.),
G Saracco, and F Rosina, and M R Torrani Cerenzia, and V Lattore, and L Chiandussi, and V Gallo, and R Petrino, and A G De Micheli, and E Donegani, and A Solinas
Interferon alfa-2b therapy in children with chronic hepatitis B.
January 1993, Gut,
G Saracco, and F Rosina, and M R Torrani Cerenzia, and V Lattore, and L Chiandussi, and V Gallo, and R Petrino, and A G De Micheli, and E Donegani, and A Solinas
A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group.
August 1990, The New England journal of medicine,
G Saracco, and F Rosina, and M R Torrani Cerenzia, and V Lattore, and L Chiandussi, and V Gallo, and R Petrino, and A G De Micheli, and E Donegani, and A Solinas
Therapy of chronic post-transfusion non-A, non-B hepatitis with interferon alfa-2b: Swedish experience.
January 1990, Journal of hepatology,
G Saracco, and F Rosina, and M R Torrani Cerenzia, and V Lattore, and L Chiandussi, and V Gallo, and R Petrino, and A G De Micheli, and E Donegani, and A Solinas
One-year treatment of chronic non-A, non-B hepatitis with interferon alfa-2b.
January 1990, Journal of hepatology,
Copied contents to your clipboard!